Mursla Bio, a leading innovator in the field of diagnostics and precision medicine, has recently published a peer-reviewed paper in the interdisciplinary journal iScience, which is affiliated with Cell Press. The paper highlights the company’s cutting-edge technology for analyzing extracellular vesicles (EV) sub-types found in biofluids like blood. EVs play a crucial role in intercellular communication and are poised to revolutionize disease diagnostics.
The paper introduces Nano-Extracellular Omics Sensing (NEXOS), an electro-optical platform that enables sensitive detection and quantification of EV proteins. This groundbreaking and scalable technology addresses previous limitations in the detection of EV proteins, providing new insights into liquid biopsies and enhancing their use in clinical contexts.
Mursla Bio is currently conducting a clinical study on liver cancer, with additional peer-reviewed papers expected to be published in support of this research. The company’s focus is on decoding extracellular vesicles to develop curative treatments for cancer. They have developed a first-of-its-kind blood test that enables non-invasive liver biopsies based on the analysis of liver-derived EVs. This test aims to replace ultrasound for monitoring liver cancer in high-risk patients in Western countries.
Mursla Bio has been recognized as the UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category, highlighting their leadership position at the forefront of liquid biopsy technology. For more information about Mursla Bio and their innovative solutions, visit their website at mursla.com.
